ISIS Related Analyst Ratings
-
Analyst Cautiously Optimistic on ISIS (ISIS) SMN (Rx)
-
Cowen Upgrades ISIS Pharmaceuticals (ISIS) to Outperform
-
Isis Pharmaceuticals (ISIS) on Traders Radars Ahead of Cramer Mad Money Interview
-
Needham Reiterates Buy on ISIS (ISIS) Following Narrow FDA Vote for Approval of Kynamro
-
Jefferies Cuts Numbers on ISIS Pharmaceuticals (ISIS) Despite Panel Backing
-
Summer Street Cuts ISIS Pharmaceuticals (ISIS) to Neutral
-
Piper Jaffray Downgrades ISIS Pharmaceuticals (ISIS) to Overweight
-
JMP Securities Starts ISIS Pharmaceuticals (ISIS) at Market Perform
-
Canaccord Genuity Maintains Hold and Raises Price Target on ISIS Pharmaceuticals (ISIS)
-
Jefferies Downgrades ISIS Pharmaceuticals (ISIS) Two-Notches to Underperform
-
Needham & Company Starts ISIS Pharmaceuticals (ISIS) at Buy; Looking Beyond Kynamro at Significant Pipeline Value
-
Correction - Canaccord Genuity maintains a 'Hold' on ISIS Pharmaceuticals (ISIS)
-
Canaccord Genuity Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Adjusting Estimates After Top & Bottom Line Beat
-
Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight
-
Canaccord Genuity Starts ISIS Pharmaceuticals (ISIS) at Hold
-
Jefferies Cuts Price Targets on ISIS Pharmaceuticals (ISIS), Has Enough Cash Through 2014
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); 2Q11/Early 3Q11 Review - Mipomersen Application in EU (Submitted) and US (Expected by YE11)
-
Global Hunter Securities Starts Aegerion Pharmaceuticals (AEGR) at Buy; Lomitapide – A Potential Best-in-Class Drug
-
Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipeline Progress Review – Long-Term, Early Stage Programs Are Encouraging
-
Barclays Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); 4Q10 Update - Mipomersen Filings on Track
-
Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Strong Focus on Mipomersen Next Steps by Genzyme, Steady Progress of Early-Stage Pipeline
-
Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
-
Needham & Company Reiterates a 'Hold' on ISIS Pharmaceuticals (ISIS); FDA Views Mipomersen Data as Sufficient to Submit HoFH NDA
-
Collins Stewart Downgrades ISIS Pharmaceuticals (ISIS) to Hold
-
Piper Jaffray Cuts Isis Pharma (ISIS) to Neutral
-
Shares of Isis Pharma (ISIS) Volatile Following Mid-Day Downgrade by Needham
-
Morgan Joseph Adds Onyx Pharma (ONXX) to 'Trading List' Following Positive Data on Carfilzomib
-
Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS), Well Positioned to Address Genetic Disorders
-
Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Annual Meeting Highlighted
-
Citi 2010 Healthcare Conference Key Takeaways - MRK, PFE, BMY, ISIS, NPSP, & MYGN
-
Needham & Company Reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Pipelines to Address Cancer Through Antisense Technology
-
Needham & Company reiterates a 'Buy' on ISIS Pharmaceuticals (ISIS); Cardiovascular Program Update – Multiple Well-Characterized Drug Candidates
-
Analysts Thoughts On Isis Pharmaceuticals (ISIS) After 19% Sell-Off
-
Morgan Joseph Reiterates a 'Buy' on Isis Pharmaceuticals (ISIS); Could Be Acquired by Potential Partners
-
Piper Jaffray Maintains an 'Overweight' on ISIS Pharmaceuticals (ISIS); Price Target Cut
-
Cantor Fitzgerald Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Buy; Milestones & Potential Near-term Catalysts
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Thomas Weisel Starts Isis Pharma (ISIS) at Overweight
-
Citi Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Hold, May Become Core Biotech Holding When Profitable
-
Morgan Joseph Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Buy
-
Collins Stewart Initiates Coverage on Isis Pharmaceuticals (ISIS) with a Buy
-
Needham Upgrades ISIS Pharmaceuticals (ISIS) to Buy
-
BWS Financial Comments Positively on Isis Pharmaceuticals (ISIS); Maintains Buy
-
Color on Boenning & Scattergood Upgrade of ISIS Pharma (ISIS) to Market Perform
-
Boenning & Scattergood Upgrades ISIS Pharmaceuticals (ISIS) to Market Perform
-
Needham Downgrades ISIS Pharma (ISIS) to Hold On Mipomersen Delays
-
Piper Jaffray Tells Clients To Buy ISIS Pharma (ISIS) On Today's Weakness
-
Leerink Swann Downgrades Isis Pharmaceuticals (ISIS) to Market Perform
-
Natixis Bleichroeder upgrades ISIS Pharmaceuticals (ISIS) to Hold
Back to ISIS Stock Lookup
